|

Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)

RECRUITINGSponsored by Universidade do Porto
Actively Recruiting
SponsorUniversidade do Porto
Started2024-07-01
Est. completion2024-10-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06498167

Summary

The LOOK-UP is an investigator-initiated clinical study with the aim of monitoring the post-marketing safety of the medicine Rinvoq™ (upadacitinib), which is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, atopic dermatitis, ulcerative colitis, and Crohn's disease. The Marketing Authorisation Holder is AbbVie Deutschland GmbH \& Co. KG.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Prescription of Rinvoq™ from January 1, 2024;
* 18 years of age or older at the time of recruitment; and
* Expressed consent to participate in the study.

Exclusion Criteria:

* They have any degree of cognitive impairment that prevents them from responding to a questionnaire administered by telephone;
* They are participating in a phase I, II, or III clinical trial;
* They have a life expectancy of less than 1 month; or
* They do not have a valid telephone contact.

Conditions7

Adverse Drug EventAdverse Drug ReactionArthritisDrug Side EffectDrug UseInflammatory DiseaseSafety Issues

Browse More Trials

Arthritis trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.